NO20045229L - Fusjonsprotein fra HIV-regulatoriske/aksessoriske proteiner - Google Patents
Fusjonsprotein fra HIV-regulatoriske/aksessoriske proteinerInfo
- Publication number
- NO20045229L NO20045229L NO20045229A NO20045229A NO20045229L NO 20045229 L NO20045229 L NO 20045229L NO 20045229 A NO20045229 A NO 20045229A NO 20045229 A NO20045229 A NO 20045229A NO 20045229 L NO20045229 L NO 20045229L
- Authority
- NO
- Norway
- Prior art keywords
- proteins
- fusion protein
- nucleic acids
- hiv
- accessory proteins
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 230000001105 regulatory effect Effects 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200754 | 2002-05-16 | ||
| PCT/EP2003/005039 WO2003097675A1 (en) | 2002-05-16 | 2003-05-14 | Fusion protein of hiv regulatory/accessory proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20045229L true NO20045229L (no) | 2004-11-29 |
Family
ID=29433046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045229A NO20045229L (no) | 2002-05-16 | 2004-11-29 | Fusjonsprotein fra HIV-regulatoriske/aksessoriske proteiner |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US20050222388A1 (ja) |
| EP (2) | EP1652857B9 (ja) |
| JP (3) | JP2006502704A (ja) |
| KR (4) | KR20100063126A (ja) |
| CN (3) | CN1982332A (ja) |
| AT (2) | ATE407143T1 (ja) |
| AU (2) | AU2003240638B2 (ja) |
| BR (1) | BR0309963A (ja) |
| CA (1) | CA2483640A1 (ja) |
| CY (1) | CY1108638T1 (ja) |
| DE (2) | DE60323407D1 (ja) |
| DK (2) | DK1506223T3 (ja) |
| EA (1) | EA007154B1 (ja) |
| ES (2) | ES2253675T3 (ja) |
| HK (1) | HK1076822A1 (ja) |
| IL (3) | IL164178A0 (ja) |
| MX (1) | MXPA04010683A (ja) |
| NO (1) | NO20045229L (ja) |
| NZ (2) | NZ556144A (ja) |
| PL (2) | PL372092A1 (ja) |
| PT (1) | PT1652857E (ja) |
| SI (2) | SI1506223T1 (ja) |
| UA (3) | UA92788C2 (ja) |
| WO (1) | WO2003097675A1 (ja) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| EP1652857B9 (en) * | 2002-05-16 | 2009-10-14 | Bavarian Nordic A/S | Fusion protein of HIV regulatory/accessory proteins |
| ATE520708T1 (de) | 2003-03-28 | 2011-09-15 | Us Gov Health & Human Serv | Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung |
| CN101330830B (zh) | 2005-10-18 | 2016-01-20 | 国家犹太健康中心 | 条件无限增殖化长期干细胞和制备和使用所述细胞的方法 |
| AU2007345768B2 (en) * | 2006-07-27 | 2013-08-01 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
| EP2044224A4 (en) * | 2006-07-27 | 2011-04-13 | Ligocyte Pharmaceuticals Inc | CHIMERIC VIRUS TYPE PARTICLES |
| CA2723114C (en) | 2008-05-16 | 2018-02-27 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| EP2746387A1 (en) | 2008-07-21 | 2014-06-25 | Taiga Biotechnologies, Inc. | Differentiated anucleated cells and method for preparing the same |
| ES2681478T3 (es) | 2008-08-28 | 2018-09-13 | Taiga Biotechnologies, Inc. | Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC |
| EP2486138A1 (en) | 2009-10-08 | 2012-08-15 | Bavarian Nordic A/S | Generation of a broad t-cell response in humans against hiv |
| US9358281B2 (en) * | 2009-10-09 | 2016-06-07 | New York University | Methods, agents and peptides for inducing an innate immune response in HIV vaccination |
| US8920812B2 (en) | 2009-11-03 | 2014-12-30 | Takeda Vaccines, Inc. | Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| CN114645015A (zh) | 2012-07-20 | 2022-06-21 | 泰加生物工艺学公司 | 造血区室的增强的重建和自动重建 |
| US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| WO2015192339A1 (zh) * | 2014-06-18 | 2015-12-23 | 中山大学 | 一种嵌合载体及其制备方法和应用 |
| CN104130331B (zh) * | 2014-06-19 | 2017-06-06 | 中山大学 | 一种抗hiv‑1病毒药物及其制备和应用 |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| CN105330729A (zh) * | 2015-11-18 | 2016-02-17 | 南京医科大学 | 一种人类免疫缺陷病毒Vpr蛋白的制备方法 |
| US10583156B2 (en) | 2016-12-02 | 2020-03-10 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| US11666651B2 (en) | 2019-11-14 | 2023-06-06 | Aelix Therapeutics, S.L. | Prime/boost immunization regimen against HIV-1 utilizing a multiepitope T cell immunogen comprising Gag, Pol, Vif, and Nef epitopes |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0942747A1 (en) * | 1996-08-26 | 1999-09-22 | Chiron Corporation | Postinfection human immunodeficiency virus (hiv) vaccination therapy |
| GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
| IT1297090B1 (it) | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
| FR2773156B1 (fr) * | 1997-12-26 | 2000-03-31 | Biovacs Inc | Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida |
| FI105105B (fi) | 1998-02-27 | 2000-06-15 | Finnish Immunotechnology Ltd O | Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan |
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| SK11122002A3 (sk) | 2000-01-31 | 2003-01-09 | Smithkline Beecham Biologicals S. A. | Použitie HIV Tat proteínu a/alebo HIV Nef proteínu spolu s HIV gp120 proteínom a vakcína obsahujúca tieto proteíny |
| EP1418940A4 (en) * | 2000-03-02 | 2006-09-20 | Univ Emory | DNA expression vectors and methods of use |
| US6544780B1 (en) * | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
| ES2307640T3 (es) * | 2000-07-14 | 2008-12-01 | The Trustees Of The University Of Pennsylvania | Vacunad de adn codificantes de proteinas accesorias del vih. |
| WO2002036806A2 (en) * | 2000-11-01 | 2002-05-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Expression vectors able to elicit improved immune response and methods of using same |
| US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| EP1652857B9 (en) | 2002-05-16 | 2009-10-14 | Bavarian Nordic A/S | Fusion protein of HIV regulatory/accessory proteins |
-
2003
- 2003-05-14 EP EP05017695A patent/EP1652857B9/en not_active Expired - Lifetime
- 2003-05-14 CN CNA200710000639XA patent/CN1982332A/zh active Pending
- 2003-05-14 DK DK03730029T patent/DK1506223T3/da active
- 2003-05-14 IL IL16417803A patent/IL164178A0/xx active IP Right Grant
- 2003-05-14 ES ES03730029T patent/ES2253675T3/es not_active Expired - Lifetime
- 2003-05-14 KR KR1020107008995A patent/KR20100063126A/ko not_active Application Discontinuation
- 2003-05-14 EA EA200401504A patent/EA007154B1/ru not_active IP Right Cessation
- 2003-05-14 KR KR1020047017968A patent/KR100996330B1/ko not_active IP Right Cessation
- 2003-05-14 UA UAA200811374A patent/UA92788C2/ru unknown
- 2003-05-14 WO PCT/EP2003/005039 patent/WO2003097675A1/en active Application Filing
- 2003-05-14 EP EP03730029A patent/EP1506223B1/en not_active Expired - Lifetime
- 2003-05-14 DE DE60323407T patent/DE60323407D1/de not_active Expired - Lifetime
- 2003-05-14 NZ NZ556144A patent/NZ556144A/en not_active IP Right Cessation
- 2003-05-14 CN CNB038111195A patent/CN1325512C/zh not_active Expired - Fee Related
- 2003-05-14 SI SI200330168T patent/SI1506223T1/sl unknown
- 2003-05-14 CA CA002483640A patent/CA2483640A1/en not_active Abandoned
- 2003-05-14 DE DE60302356T patent/DE60302356T2/de not_active Expired - Lifetime
- 2003-05-14 JP JP2004506348A patent/JP2006502704A/ja active Pending
- 2003-05-14 AT AT05017695T patent/ATE407143T1/de active
- 2003-05-14 UA UA20041109408A patent/UA85373C2/ru unknown
- 2003-05-14 PL PL03372092A patent/PL372092A1/xx not_active IP Right Cessation
- 2003-05-14 UA UA20041109410A patent/UA82998C2/ru unknown
- 2003-05-14 AT AT03730029T patent/ATE310016T1/de active
- 2003-05-14 ES ES05017695T patent/ES2313166T3/es not_active Expired - Lifetime
- 2003-05-14 KR KR1020117017944A patent/KR101196178B1/ko not_active IP Right Cessation
- 2003-05-14 DK DK05017695T patent/DK1652857T3/da active
- 2003-05-14 MX MXPA04010683A patent/MXPA04010683A/es active IP Right Grant
- 2003-05-14 NZ NZ536499A patent/NZ536499A/en not_active IP Right Cessation
- 2003-05-14 US US10/514,740 patent/US20050222388A1/en not_active Abandoned
- 2003-05-14 KR KR1020127021229A patent/KR20120106894A/ko not_active Application Discontinuation
- 2003-05-14 PT PT05017695T patent/PT1652857E/pt unknown
- 2003-05-14 PL PL397252A patent/PL397252A1/pl not_active Application Discontinuation
- 2003-05-14 SI SI200331443T patent/SI1652857T1/sl unknown
- 2003-05-14 CN CNA2007101039526A patent/CN101108882A/zh active Pending
- 2003-05-14 AU AU2003240638A patent/AU2003240638B2/en not_active Ceased
- 2003-05-14 BR BR0309963-6A patent/BR0309963A/pt not_active IP Right Cessation
-
2004
- 2004-09-21 IL IL164178A patent/IL164178A/en not_active IP Right Cessation
- 2004-11-29 NO NO20045229A patent/NO20045229L/no not_active Application Discontinuation
-
2005
- 2005-09-30 HK HK05108707A patent/HK1076822A1/xx not_active IP Right Cessation
-
2006
- 2006-07-18 US US11/488,803 patent/US7569228B2/en not_active Expired - Fee Related
-
2008
- 2008-12-03 CY CY20081101401T patent/CY1108638T1/el unknown
- 2008-12-04 AU AU2008252074A patent/AU2008252074B2/en not_active Ceased
-
2009
- 2009-02-26 IL IL197304A patent/IL197304A0/en unknown
- 2009-05-11 JP JP2009114359A patent/JP2009178165A/ja active Pending
- 2009-06-24 US US12/490,424 patent/US8143054B2/en not_active Expired - Fee Related
- 2009-11-03 US US12/611,188 patent/US8137931B2/en not_active Expired - Fee Related
- 2009-11-03 US US12/611,164 patent/US8147839B2/en not_active Expired - Fee Related
- 2009-12-22 JP JP2009290256A patent/JP2010099084A/ja active Pending
-
2012
- 2012-02-14 US US13/372,723 patent/US8435535B2/en not_active Expired - Fee Related
- 2012-02-14 US US13/372,706 patent/US8389275B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20045229L (no) | Fusjonsprotein fra HIV-regulatoriske/aksessoriske proteiner | |
| CY1124518T1 (el) | Μεταλλαγες πρωτεϊνης φακελου hiv που σταθεροποιουν το τριμερες | |
| NO20071369L (no) | Antimikrobiske peptider omfattende et arginin- og/eller lysin-inneholdende motiv | |
| DK1328543T3 (da) | Nukleinsyrer og proteiner fra streptococcus-gruppe A & B | |
| NO20062044L (no) | Piscirickettsia salmonis-antigener og anvendelse derav | |
| PE20060816A1 (es) | Proceso para la concentracion de anticuerpos y productos terapeuticos de los mismos | |
| NO20063026L (no) | Antistoffer | |
| NO20052149L (no) | Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein. | |
| WO2007149491A3 (en) | Soluble stabilized trimeric hiv env proteins and uses thereof | |
| BR112018013246A2 (ja) | Tag addition protein containing a peptide tag and it | |
| PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
| Gupta | Immunology of HIV infection | |
| CY1106175T1 (el) | Αλληλουχιες νουκλεϊνικου οξεος και αμινοξεος μολυσματικου ιου αναιμιας σολομων και χρηση τους ως εμβολια | |
| EA200600738A1 (ru) | Способ | |
| CO5650177A2 (es) | Constructos geneticos y composiciones que comprenden rre y cte y usos de estos | |
| BR112023022367A2 (pt) | Anticorpos anti-tigit e métodos de uso dos mesmos | |
| NO20083576L (no) | Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav | |
| WO2022238966A3 (en) | Cytomegalovirus t cell epitopes and uses thereof | |
| WO2023038961A3 (en) | Common cold coronavirus t cell epitopes, methods and uses thereof | |
| ATE419363T1 (de) | Pharmazeitische impfstoffe gegen hiv | |
| WO2020144355A3 (fr) | Peptides immunogènes issus de la nucléoprotéine du virus ebola zaïre | |
| WO2024081938A3 (en) | Protein scaffolds for disordered regions | |
| Jeon | Symbiosis and macromolecules | |
| CY1113749T1 (el) | Συνθεσεις εμβολιων dna και μεθοδοι χρησης τους | |
| within Arenavirus | Identification of an N-Terminal Trimeric |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |